| 前收市價 | 259.50 |
| 開市 | 248.50 |
| 買盤 | 252.30 x 5000 |
| 賣出價 | 254.70 x 5000 |
| 今日波幅 | 248.50 - 248.50 |
| 52 週波幅 | 248.50 - 383.80 |
| 成交量 | |
| 平均成交量 | 8 |
| 市值 | 6.868B |
| Beta 值 (5 年，每月) | 0.94 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -9.94 |
| 業績公佈日 | 2024年8月01日 - 2024年8月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 856.25 |
ZacksBio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down
Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.
Insider MonkeyBio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2024 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2024 Earnings Call Transcript May 7, 2024 Bio-Rad Laboratories, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon everyone, and welcome to today’s Bio-Rad First Quarter 2024 Earnings Results Conference Call. At this […]
ZacksBio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
Bio-Rad (BIO) delivered earnings and revenue surprises of 12.25% and 0.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
